Should Immunoglobulin Therapy Be Used in Allogeneic Stem-Cell Transplantation? A Randomized, Double-Blind, Dose Effect, Placebo-Controlled, Multicenter Trial

Annals of Internal Medicine

Volumn 139, Issue 1, 2003, Pages

  Cordonnier, Catherine ^a,b   Chevret, Sylvie ^a   Legrand, Marc ^a   Rafi, Homa ^a   Dhédin, Nathalie ^a   Lehmann, Blandine ^a   Bassompierre, François ^a   Gluckman, Eliane ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GENTAMICIN; IMMUNOGLOBULIN; METHOTREXATE; NEOMYCIN; PLACEBO; POLYENE ANTIBIOTIC AGENT; HLA ANTIGEN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAPHYLACTIC SHOCK; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; FEMALE; FEVER; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEADACHE; HLA TYPING; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; SHIVERING; SIBLING; VEIN OCCLUSION; VOMITING; ALLOTRANSPLANTATION; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; INTERSTITIAL LUNG DISEASE; LIVER VEIN OBSTRUCTION; PATIENT; PATIENT COMPLIANCE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUNG DISEASES, INTERSTITIAL; MALE; PATIENT COMPLIANCE; PATIENT DROPOUTS; PLACEBOS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0038819950     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-1-200307010-00007     Document Type: Article

References (40)

1. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705-12. [PMID: 2167452]
2. Emanuel D, Taylor J, Brochstein J, Kernan N, Boulad F, Small T, et al. The use of intravenous immune globulin as prophylaxis for the infectious complications of allogeneic marrow transplantation [Abstract]. Blood. 1992;80(Suppl 1):271a.
3. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106:12-8. [PMID: 3024542]
4. Kubanek B, Ernst J, Ostendorf P, Schfer U, Wolf H. Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow rransplant recipients. Transplant Proc. 1985;17:468-9.
5. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179-84. [PMID: 8380243]
6. Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 1993;12:273-82. [PMID: 8241987]
7. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant. 1994;13:499-510. [PMID: 8054903]
8. Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant. 1999;23:929-32. [PMID: 10338049]
9. Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28:187-96. [PMID: 11509937]
10. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827-38. [PMID: 8114836]
11. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-17. [PMID: 6996481]
12. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255-67. [PMID: 8420443]
13. Lungman P, Griffiths P. Definitions of cyromegalovirus infection and disease. In: Michelson S, Plotkin S, eds. Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Amsterdam: Excerpta Medica International Congress Series; 1993:233-7.
14. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics. 1988;16:1141-54.
15. Aalen O. Nonparametric estimation of partial transition probabilities in multiple decrement models. Annals of Statistics. 1978;6:534-45.
16. Andersen PK, Gill R. Cox's regression model for counting processes: A large sample study. Annals of Statistics. 1982;10:1100-20.
17. Klein JP. Small sample moments of some esrimators of the variance of the Kaplan-Meier and Nelson-Aalen estimators. Scandinavian Journal of Statistics. 1991;18:333-40.
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the, American Statistical Association. 1999;94:496-509.
19. Gray RJ. cmprsk Package [serial on line] 2001. Boston: Department of Biostatistical Science, Dana-Farber Cancer Institute. Accessed at http://biowww.dfci.harvard.edu/~gray on 1 May 2003.
20. Akhan H, Cordonnier C. Antimicrobial prophylaxis in EBMT centers: a report from the EBMT Infectious Diseases Working Party [Abstract]. Bone Marrow Transplant. 2001;27(Suppl 1):S202.
21. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant. 1996;2:44-53. [PMID: 9078354]
22. Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV CIMV infection and disease after marrow transplant. J Infect Dis. 1991;164:483-7. [PMID: 1651360]
23. Feinstein LC, Seidel K, Jocum J, Bowden RA, Anasetti C, Deeg HJ, et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant. 1999;5:369-78. [PMID: 10595814]
24. Boeck M, Ljungman P. Cytomegalovirus infection after bone marrow transplantation. In: Bowden R, Paya C, Ljungman P, eds. Transplant Infections. Philadelphia: Lippincort-Raven; 1998:215-27.
25. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601-7. [PMID: 1658652]
26. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-51. [PMID: 1542320]
27. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545-52. [PMID: 7769290]
28. Meyers JD, Leszczynski J, Zaia JA, Flournoy N, Newton B, Snydman DR, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med. 1983;98:442-6. [PMID: 6301320]
29. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006-10. [PMID: 3007984]
30. Winston DJ, Pollard RB, Ho WG, Gallagher JG, Rasmussen LE, Huang SN, et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med. 1982;97:11-8. [PMID: 6283982]
31. Condie RM, O'Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. Am J Med. 1984;76:134-41. [PMID: 6324587]
32. Ringden O, Pihlstedt P, Volin L, Nikoskelainen J, Lonnqvist B, Ruutu P, et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant. 1987;2:299-305. [PMID: 2844340]
33. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159-64. [PMID: 11830461]
34. Sullivan K, Seidel K, Jocom J, Anasetti C, Hansen J, Storb R, et al. Intravenous immunogtobulin prophylaxis in unrelated donor bone marrow transplantation: a phase III double-blind, placebo-controlled multi-institutional trial [Abstact]. In: Proceedings of the Thirty-sixth Annual Meeting of the American Society of Clinical Oncology. New Orleans: 20-23 May 2000. J Clin Oncol. 2000;19:47a.
35. Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med. 1993;118:937-42. [PMID: 8489107]
36. Klaesson S, Ringden O, Ljungman P, Aschan J, Hägglund H, Winiarski J. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation. 1995;60:1225-30. [PMID: 8525515]
37. Sullivan KM, Kansu E, Storer B, Jocom J, Emerson G, Reagan T, et al. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Biol Blood Marrow Transplant. 1998;4:20-6. [PMID: 9701388]
38. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011-6. [PMID: 2405918]
39. Aukrust P, Froland S, Liabakk N, Muller F, Nordoy I, Haug C, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994;84:2136-43. [PMID: 7919327]
40. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49:1-125, CE1-7. [PMID: 11718124]